Transforming Growth Factor beta1
"Transforming Growth Factor beta1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subtype of transforming growth factor beta that is synthesized by a wide variety of cells. It is synthesized as a precursor molecule that is cleaved to form mature TGF-beta 1 and TGF-beta1 latency-associated peptide. The association of the cleavage products results in the formation a latent protein which must be activated to bind its receptor. Defects in the gene that encodes TGF-beta1 are the cause of CAMURATI-ENGELMANN SYNDROME.
Descriptor ID |
D053773
|
MeSH Number(s) |
D12.644.276.374.687.100 D12.644.276.954.775.100 D12.776.467.374.687.100 D12.776.467.942.775.100 D23.529.374.687.100 D23.529.942.775.100
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Transforming Growth Factor beta1".
Below are MeSH descriptors whose meaning is more specific than "Transforming Growth Factor beta1".
This graph shows the total number of publications written about "Transforming Growth Factor beta1" by people in this website by year, and whether "Transforming Growth Factor beta1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 0 | 1 | 1 |
2005 | 0 | 1 | 1 |
2006 | 0 | 3 | 3 |
2008 | 0 | 3 | 3 |
2010 | 0 | 1 | 1 |
2011 | 1 | 0 | 1 |
2014 | 1 | 0 | 1 |
2018 | 0 | 1 | 1 |
2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Transforming Growth Factor beta1" by people in Profiles.
-
Novel Roles of Follistatin/Myostatin in Transforming Growth Factor-ß Signaling and Adipose Browning: Potential for Therapeutic Intervention in Obesity Related Metabolic Disorders. Front Endocrinol (Lausanne). 2021; 12:653179.
-
MicroRNA-942 mediates hepatic stellate cell activation by regulating BAMBI expression in human liver fibrosis. Arch Toxicol. 2018 09; 92(9):2935-2946.
-
The transcriptional signatures of cells from the human Peyronie's disease plaque and the ability of these cells to generate a plaque in a rat model suggest potential therapeutic targets. J Sex Med. 2015 Feb; 12(2):313-27.
-
Amelioration of diabetes-induced cavernosal fibrosis by antioxidant and anti-transforming growth factor-ß1 therapies in inducible nitric oxide synthase-deficient mice. BJU Int. 2012 Feb; 109(4):586-93.
-
The genetic inactivation of inducible nitric oxide synthase (iNOS) intensifies fibrosis and oxidative stress in the penile corpora cavernosa in type 1 diabetes. J Sex Med. 2010 Sep; 7(9):3033-44.
-
Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells. J Endocrinol. 2009 Feb; 200(2):207-21.
-
Profibrotic role of myostatin in Peyronie's disease. J Sex Med. 2008 Jul; 5(7):1607-22.
-
Myostatin promotes a fibrotic phenotypic switch in multipotent C3H 10T1/2 cells without affecting their differentiation into myofibroblasts. J Endocrinol. 2008 Feb; 196(2):235-49.
-
Increased vaginal oxidative stress, apoptosis, and inducible nitric oxide synthase in a diabetic rat model: implications for vaginal fibrosis. Fertil Steril. 2006 Oct; 86(4 Suppl):1152-63.
-
Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. Hepatology. 2006 Aug; 44(2):420-9.